- Email: [email protected]
Bronchoalveolar lavage in the diagnosis of low-grade, MALT type, B-cell lymphoma in the lung
334
Abstrocrs/Lmg
Gmcer 13 (1995) 323-356
factor (TNFJ 8. Semiquantitative comperisons between patients’ TIL and PBL and healthy normal and activated PBL were performed by computerized image analysis. RT-FCRgel band products were quantified in relative units as a won of their size and intensity. TIL expressed deteaable lymphokine mRNA but seemed poorly activated with respect to the total number of lymphokine genes and the amount of mRNA compared with -3-activated healthy PBL. IL-2, IFNpamma, and TNF8 did not appear to be expressed at higher levels in TIL than in autologous or healthy normal PBL. However, two-thirds of the patients had TIL distinguishable from autologous PBL by specific expression of GM-CSF and from healthy normal PBL by expression of IL-~. These <s show that lung adenocarcinoma TIL populations had little lymphokine gent a&-&ion despite the pnsare of seveml T cdl subsets expressing different adhesionhctivation markers. The lack or deficient combination of lymphokine production may be a faaor that prevented efRcient activation of TIL in these tumors. Broachoaiveolar Iavage fluid level of carcinoembryonic antigen in the di8gnoris of peripheral lung cancer Sanguinetti CM, Riccioni G, Marchesani F, Pela R, Cecarini L. Divisione di Pneumologia, Ospedale ‘SS Benvenuto e Rocco : bia Leopanii, 1.5, 60027 Osimo (AN). Monaldi Arch Chest Dis 1995;50:177-82. The objective of this study was to verify whether the assay of carcinoembryonic antigen (CEA) in bronchoalveolar lavage fluid (BALF) can increase the sensitivity and specificity of serum CEA for the diagnosis of lung cancer. We examined 72 subjects, 53 males and 19 females, 18 at&&d with peripheral lung cancer (10 adenecarcinoma, 6 squamous eel1 carcinoma, 1 small cell lung cancer, 1 adenosquamous carcinoma), 19 with acute pneumonia, 14 with chronic obstructive pulmonary disease (COPD), 6 with interstitial lung disease (ILD), and 15 healthy subjects. CEA was assayed in blood and in BALF using microparticle eozyme immuooassay (IvfEIA) (IMX Abbott). The mean semm CEA value in the lung cancer group did not differ from that in each group of non-neoplastic subjects, neither was it different from that in healthy subjects. The mean BALF CEA in patients with lung cancer, pneumonia, and CGPD was significantly increased compared with that in healthy subjects, whereas there was no difference between the three groups of patients. The mtio of BALF CEA was not signiticantly &rent in the three groups of patients. There were no differences according to the histological type of the tumour (adenocarcinoma or squamous cell carcinoma). Based on the results in healthy subjects, the upper limits of normal were delined for serum CEA, BALF CEA, and CEA/albumin ratio, Tlms, the sensitivity of BALF CEA in de.tecdng lung cancer (50%) was higher than that ofsenrm CEA (33%). although clinically not useful. In addition, BALF CEA had only 59% specificity compared to 100% of sennn CEA. The diagnostic accuracy was 79% for serum CEA and 56%for BALF CEA. The assay of CEA in bronchoalveolar lavage fluid is slightly mofc sensitive but less specific than serum CEA, and does not seem to be any better than serum CEA in the diagnosis of peripheral lung cancer. Bronchoalveolar Iavage in the diagnosis of low-grade, MALT tyw B-cell lymphoma in the lung Poletti V, Romagna M, Gasponi A, Baruzzi G, Allen KA. Divisione di Pneumologia, Ospedale Maggiom. L.atgo Nigrisoli 2, 40133, Bologna. Monaldi Arch Chest Dis 1995:50: 191-4. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type represents one of the most frequent primary lymphomas in the lung. This study demonstrates the value of bronchoalveolar lavage (BAL) in the diagnosis of this entity, Tluoe patients with biopsy p&en MALT lymphoma in the lung were submitted to bronchoscopy. BAL fluid analysis showed an increased cellularity and a striking
lymphocytosis. Cytological features consistent with a low-grade malignant lymphomawcre present in two cases (odium sized lymphoid cells with an evident lymphoplasmocytoid differentiation, and irregular nuclear borders), In all QLses, flow cytometry analysis showed a high percentage of cells expressing a B phenotype (52, 40 and 28%, mpeetively). In twu cases, there was a striking monotypic expression of surface light-chain immunoglobulin (Kapm ratio = 38 and 0.04, respectively). Bronchoalveolar lavage appears to be a valuable procedure in the diagnosis of low-grade B-cell lymphoma of MALT type in the lung.
Expression of several biologic markers as prognostic markers in non-small cell lung cancexs Kim SY, Cho HI, Sub JW, Kim NJ, Kim JO. Deparfment of Inremal Medicine, Chungnam National University, School of Medicine, Taejon. lbberc Reapir Dis 1995;42:142-8. Backgmund Despite modem diagnostic, staging, and therapeutic advances, esp. with molecular biologic techniques& 5-year survival rateofallcasesoflungcamrrdoesnotex~15$6.Al~,tbeiacidence 0fhmgcancerofbothsexesinKorcais -YearbyYaand hIrIg cancer is One of the leding causes of cancer death. Thcreforc, it is stronglyneededt0deve1opulenewu&iitionof&atmont modaliues including neoadjuvant chemotherapy and to identiQ tumor specific cbaraaeristics with staging or pmgnostic markers. Here we present the clinical significance of several biologic tumor markers to use as prognostic markers in patients with non-small cell lung cantors. MCthOd: The smvival has unrelated with the expressibility of proliferative cell nuclear antigen (PCNA), epidermal growth factor wr (EGFR), ~53 and/or blood group antigen A (BGAA) using immumhistochanistly in 46 patients with non-small cell lung cancers. Results: (1) The expression rates ofPCNA, EGFR, ~53 and BGAA were 80.6%. 61.3%. 45.9% and 64.3% respecuvely and those wre wt collated to cell types or clinical stages. (2) The expression of BGAA was correlated withbettersunivalinmedianswivalandin2-yearslwivalratt~d thatdPCNAwaswmlatedwithworse~~inmediansunival and 2-year survival rate. (3) The wrpnssion of EGFR or ~53 was not valuable to predict prognosis in non-small cell lung cancers. (4) with simukamous appkatio~~ ofPCNA, EGFR and ~53 immtmosfh. the ~tientswith2ormorrne~ti~ucpresJioasshowedbetter ptugnosis than the patients with 2 or more positive ucpressions. Conclusion: It is suggested that the expression ofblood gmup antigen may be a positive prognostic fauor and that ofFCNA may be a negative progno& factor. Also, the combiion of expressions of PCNA, EGFR and ~53 may be used as a negative pmgnostic factor. Diostic due of serum CYFR4 21-l in hmg cancer YoonHD,KimKD,ChungJH,LccHw,L&KH,LeeHwdal.Dept. ojlnlemal Mealcine, College ofMedicine, Yeungnon Universi&, Taegu. Tuberc Respir Dis 1995;42: 149-55. Background: Cytokeratin 19 is 40KD acidic molecule whose distribution is restricted to simple or wtified epitholia, such as the epithelial layer of the bronchial tree. Immunomcal stwJies have shown that cytokeratin 19 is overexpressed in lung carcinoma tissue. Animmuuoradiomotricassay,CyFRA21-1 hasbeendeveloped using two moncclonal antibodies, BM 19-21 and KS 19-1, reactive to different epitopes on cytokeratin 19. We studied the diagnostic value of CYFIU 21-1 in lung cancer. Method: The serum CYFRA 21-1 level using immunoradiometric kit (ELSA-CYFRA 21-1) was measured in 54 patients who admit to Yeungnam University Hospital from April, 1993 to August, 1994. Lung cancer group was 39 primary lung canczr patients (19 patients with squamous cell carcinom 11 patients with adenodarcinoma and 9 patients with small cell carcinoma). Control
Abstrocrs/Lmg
Gmcer 13 (1995) 323-356
factor (TNFJ 8. Semiquantitative comperisons between patients’ TIL and PBL and healthy normal and activated PBL were performed by computerized image analysis. RT-FCRgel band products were quantified in relative units as a won of their size and intensity. TIL expressed deteaable lymphokine mRNA but seemed poorly activated with respect to the total number of lymphokine genes and the amount of mRNA compared with -3-activated healthy PBL. IL-2, IFNpamma, and TNF8 did not appear to be expressed at higher levels in TIL than in autologous or healthy normal PBL. However, two-thirds of the patients had TIL distinguishable from autologous PBL by specific expression of GM-CSF and from healthy normal PBL by expression of IL-~. These <s show that lung adenocarcinoma TIL populations had little lymphokine gent a&-&ion despite the pnsare of seveml T cdl subsets expressing different adhesionhctivation markers. The lack or deficient combination of lymphokine production may be a faaor that prevented efRcient activation of TIL in these tumors. Broachoaiveolar Iavage fluid level of carcinoembryonic antigen in the di8gnoris of peripheral lung cancer Sanguinetti CM, Riccioni G, Marchesani F, Pela R, Cecarini L. Divisione di Pneumologia, Ospedale ‘SS Benvenuto e Rocco : bia Leopanii, 1.5, 60027 Osimo (AN). Monaldi Arch Chest Dis 1995;50:177-82. The objective of this study was to verify whether the assay of carcinoembryonic antigen (CEA) in bronchoalveolar lavage fluid (BALF) can increase the sensitivity and specificity of serum CEA for the diagnosis of lung cancer. We examined 72 subjects, 53 males and 19 females, 18 at&&d with peripheral lung cancer (10 adenecarcinoma, 6 squamous eel1 carcinoma, 1 small cell lung cancer, 1 adenosquamous carcinoma), 19 with acute pneumonia, 14 with chronic obstructive pulmonary disease (COPD), 6 with interstitial lung disease (ILD), and 15 healthy subjects. CEA was assayed in blood and in BALF using microparticle eozyme immuooassay (IvfEIA) (IMX Abbott). The mean semm CEA value in the lung cancer group did not differ from that in each group of non-neoplastic subjects, neither was it different from that in healthy subjects. The mean BALF CEA in patients with lung cancer, pneumonia, and CGPD was significantly increased compared with that in healthy subjects, whereas there was no difference between the three groups of patients. The mtio of BALF CEA was not signiticantly &rent in the three groups of patients. There were no differences according to the histological type of the tumour (adenocarcinoma or squamous cell carcinoma). Based on the results in healthy subjects, the upper limits of normal were delined for serum CEA, BALF CEA, and CEA/albumin ratio, Tlms, the sensitivity of BALF CEA in de.tecdng lung cancer (50%) was higher than that ofsenrm CEA (33%). although clinically not useful. In addition, BALF CEA had only 59% specificity compared to 100% of sennn CEA. The diagnostic accuracy was 79% for serum CEA and 56%for BALF CEA. The assay of CEA in bronchoalveolar lavage fluid is slightly mofc sensitive but less specific than serum CEA, and does not seem to be any better than serum CEA in the diagnosis of peripheral lung cancer. Bronchoalveolar Iavage in the diagnosis of low-grade, MALT tyw B-cell lymphoma in the lung Poletti V, Romagna M, Gasponi A, Baruzzi G, Allen KA. Divisione di Pneumologia, Ospedale Maggiom. L.atgo Nigrisoli 2, 40133, Bologna. Monaldi Arch Chest Dis 1995:50: 191-4. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type represents one of the most frequent primary lymphomas in the lung. This study demonstrates the value of bronchoalveolar lavage (BAL) in the diagnosis of this entity, Tluoe patients with biopsy p&en MALT lymphoma in the lung were submitted to bronchoscopy. BAL fluid analysis showed an increased cellularity and a striking
lymphocytosis. Cytological features consistent with a low-grade malignant lymphomawcre present in two cases (odium sized lymphoid cells with an evident lymphoplasmocytoid differentiation, and irregular nuclear borders), In all QLses, flow cytometry analysis showed a high percentage of cells expressing a B phenotype (52, 40 and 28%, mpeetively). In twu cases, there was a striking monotypic expression of surface light-chain immunoglobulin (Kapm ratio = 38 and 0.04, respectively). Bronchoalveolar lavage appears to be a valuable procedure in the diagnosis of low-grade B-cell lymphoma of MALT type in the lung.
Expression of several biologic markers as prognostic markers in non-small cell lung cancexs Kim SY, Cho HI, Sub JW, Kim NJ, Kim JO. Deparfment of Inremal Medicine, Chungnam National University, School of Medicine, Taejon. lbberc Reapir Dis 1995;42:142-8. Backgmund Despite modem diagnostic, staging, and therapeutic advances, esp. with molecular biologic techniques& 5-year survival rateofallcasesoflungcamrrdoesnotex~15$6.Al~,tbeiacidence 0fhmgcancerofbothsexesinKorcais -YearbyYaand hIrIg cancer is One of the leding causes of cancer death. Thcreforc, it is stronglyneededt0deve1opulenewu&iitionof&atmont modaliues including neoadjuvant chemotherapy and to identiQ tumor specific cbaraaeristics with staging or pmgnostic markers. Here we present the clinical significance of several biologic tumor markers to use as prognostic markers in patients with non-small cell lung cantors. MCthOd: The smvival has unrelated with the expressibility of proliferative cell nuclear antigen (PCNA), epidermal growth factor wr (EGFR), ~53 and/or blood group antigen A (BGAA) using immumhistochanistly in 46 patients with non-small cell lung cancers. Results: (1) The expression rates ofPCNA, EGFR, ~53 and BGAA were 80.6%. 61.3%. 45.9% and 64.3% respecuvely and those wre wt collated to cell types or clinical stages. (2) The expression of BGAA was correlated withbettersunivalinmedianswivalandin2-yearslwivalratt~d thatdPCNAwaswmlatedwithworse~~inmediansunival and 2-year survival rate. (3) The wrpnssion of EGFR or ~53 was not valuable to predict prognosis in non-small cell lung cancers. (4) with simukamous appkatio~~ ofPCNA, EGFR and ~53 immtmosfh. the ~tientswith2ormorrne~ti~ucpresJioasshowedbetter ptugnosis than the patients with 2 or more positive ucpressions. Conclusion: It is suggested that the expression ofblood gmup antigen may be a positive prognostic fauor and that ofFCNA may be a negative progno& factor. Also, the combiion of expressions of PCNA, EGFR and ~53 may be used as a negative pmgnostic factor. Diostic due of serum CYFR4 21-l in hmg cancer YoonHD,KimKD,ChungJH,LccHw,L&KH,LeeHwdal.Dept. ojlnlemal Mealcine, College ofMedicine, Yeungnon Universi&, Taegu. Tuberc Respir Dis 1995;42: 149-55. Background: Cytokeratin 19 is 40KD acidic molecule whose distribution is restricted to simple or wtified epitholia, such as the epithelial layer of the bronchial tree. Immunomcal stwJies have shown that cytokeratin 19 is overexpressed in lung carcinoma tissue. Animmuuoradiomotricassay,CyFRA21-1 hasbeendeveloped using two moncclonal antibodies, BM 19-21 and KS 19-1, reactive to different epitopes on cytokeratin 19. We studied the diagnostic value of CYFIU 21-1 in lung cancer. Method: The serum CYFRA 21-1 level using immunoradiometric kit (ELSA-CYFRA 21-1) was measured in 54 patients who admit to Yeungnam University Hospital from April, 1993 to August, 1994. Lung cancer group was 39 primary lung canczr patients (19 patients with squamous cell carcinom 11 patients with adenodarcinoma and 9 patients with small cell carcinoma). Control